Altimmune (NASDAQ:ALT) Posts Quarterly Earnings Results

Altimmune (NASDAQ:ALT) issued its quarterly earnings data on Thursday. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01, Zacks reports. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%.

Altimmune Trading Up 7.7 %

Shares of NASDAQ ALT traded up $0.46 during trading hours on Thursday, hitting $6.40. 3,819,971 shares of the company traded hands, compared to its average volume of 2,188,915. The company’s 50 day moving average price is $6.92 and its 200 day moving average price is $7.19. Altimmune has a 12 month low of $5.28 and a 12 month high of $14.84. The stock has a market capitalization of $454.81 million, a price-to-earnings ratio of -4.13 and a beta of 0.19.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Stifel Nicolaus started coverage on Altimmune in a report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target for the company. UBS Group assumed coverage on shares of Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Altimmune presently has an average rating of “Buy” and an average price target of $20.83.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.